|Bid||3.6600 x 900|
|Ask||3.6700 x 1100|
|Day's Range||3.5800 - 3.6794|
|52 Week Range||3.0200 - 6.3000|
|Beta (3Y Monthly)||2.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.57|
Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.
Inovio (INO) delivered earnings and revenue surprises of -13.33% and -7.06%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals (NASDAQ:INO) reported its latest quarterly earnings results after hours Tuesday, bringing in revenue that fell compared to the year-ago period, while the company's net loss widened, sending INO stock down more than 4% after the bell.The Plymouth Meeting, Penn.-based company said that for its fourth quarter of its fiscal 2018, it brought in sales of $2.5 million, down 71.6% from the $8.8 million it raked in during the year-ago quarter. The company added that its net loss for the period was $33 million, or 34 cents per share, which was 53.5% wider than its year-ago loss of $21.5 million, or 24 cents per share.For its fiscal 2018, Inovio Pharmaceuticals amassed sales of $30.5 million, about 27.7% lower than the company's revenue of $42.2 million over its fiscal 2017. Plus, its net loss for the fiscal year was $97 million, or $1.05 per share, which is narrower than its loss of $88.2 million, or $1.09 per diluted share for its 2017.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe company added that its total operating expenses for its fourth quarter was $32 million, slightly above the $31.7 million during the same period in 2017. For the fiscal year, Inovio Pharmaceuticals had total operating expenses of $124.6 million, below the $125.9 million from its 2017."Inovio continues to generate impressive efficacy data for HPV-related head and neck cancers, further validating our objective to be the global leader in treating HPV-related diseases," Dr. J. Joseph Kim, Inovio President and CEO.INO stock is down roughly 4.5% after the bell following the company's underwhelming quarterly results. Shares had been up about 1.1% during regular trading hours Tuesday. More From InvestorPlace * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 5 Airline Stocks In Serious Trouble * 7 Top Stocks to Buy From Goldman Sachs' Secret Portfolio Compare Brokers The post Inovio Pharmaceuticals Earnings: INO Stock Dips as Q4 Revenue Declines appeared first on InvestorPlace.
On a per-share basis, the Plymouth Meeting, Pennsylvania-based company said it had a loss of 34 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed ...
PLYMOUTH MEETING, Pa. , March 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA immunotherapies ...
The restructuring follows the Montgomery County immunotherapy company's spinout of a personalized cancer therapy company.
PLYMOUTH MEETING, Pa. , March 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Jacqueline E. Shea , PhD, as Inovio's Chief Operating Officer (COO) ...
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see fellow investors suffer a loss. Anyone whoRead More...
PLYMOUTH MEETING, Pa., March 5, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that 2018 fourth quarter and full year financial results will be released after the market close on March 12, 2019. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET, to provide a general business update, financial results, and 2019 cash burn guidance. Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines that transform the treatment and prevention of cancer and infectious disease.
PLYMOUTH MEETING, Pennsylvania, March 4, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) today announced the initiation and opening of sites to enroll the second portion of the company's Phase 3 program for VGX-3100, Inovio's DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV). The study, named REVEAL 2, is the company's confirmatory stage Phase 3 clinical study and is designed to evaluate the efficacy and safety of VGX-3100.
PLYMOUTH MEETING, Pa., March 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today the sale of additional 6.50% convertible senior notes due 2024 (the "notes"), bringing the total amount of notes sold to $78.5 million in aggregate principal amount. The additional notes, which were issued on March 1, 2019 pursuant to a partial exercise of the initial purchasers' option to purchase additional notes, are in addition to Inovio's previously announced offering of $65.0 million aggregate principal amount of notes that closed on February 19, 2019 and another $5.0 million of notes issued on that date upon the initial partial exercise of the initial purchasers' option. The additional notes were sold on the same terms in all respects as the notes previously issued on February 19, 2019, and the terms of the additional notes are identical to those previously issued.
Geneos is collaborating with the Wistar Institute in Philadelphia. The two organizations recently published proof-of-concept animal model data from preclinical testing of its platform.
Although FANG’s 2019 troubles are making headlines and Kraft Heinz Co. (NASDAQ: KHC) just roiled the market with a truly stomach-turning fourth quarter earnings report, there’s a whole universe of small-cap stocks making waves of their own. Following a blowout fourth quarter earnings report delivered earlier in the month, Invacare Corporation (NYSE: IVC) has continued generating investor interest. More impressive is that the stock gained 13 percent on top of its initial spike in the days following its earnings announcement.
PLYMOUTH MEETING, Pa., Feb. 21, 2019 /PRNewswire/ -- Geneos Therapeutics announced today that it has closed its Series A round raising $10.5 Million in financing. This funding will launch its operations as a standalone entity to develop the next generation of neoantigen-targeting cancer immunotherapies. Geneos, created as a spinout of Inovio Pharmaceuticals, Inc. (INO) will leverage a proven immunotherapy platform ("Geneos Platform") under an exclusive license from Inovio in the field of personalized treatments for cancer. The Series A Financing, which includes a committed initial investment and a milestone driven option, is led by Santé Ventures and joined by Inovio. Cancer neoantigens – the mutations and genomic changes that accumulate as tumors develop – have been recognized as important targets in the development of immune mediated treatments for cancer. These are recognized by the immune system as being foreign and generate immune responses directed at the cancer. The Geneos Platform allows the company to develop exquisitely personalized therapies tailored to each patient's own tumor mutations. The Geneos Platform is poised to deliver the following key advantages: ability to drive potent and broad T cell immune responses, capability to target an unprecedented number of neoantigens in a single formulation, and a rapid manufacturing turnaround time. Geneos, along with its collaborators at The Wistar Institute, recently published preclinical, proof-of-concept animal model data in the prestigious journal, Cancer Immunology Research, demonstrating the advantages of the Geneos Platform.
PLYMOUTH MEETING, Pa., Feb. 20, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) in collaboration with The Wistar Institute and the University of Pennsylvania announced today that the first subject was dosed as part of the first-ever human study of Inovio's DNA-encoded monoclonal antibody (dMAb™) technology. Funded fully by the Bill & Melinda Gates Foundation, this trial's focus is on evaluating the dMAb's (INO-A002) ability to prevent or treat Zika virus infection. The clinical results will also help to broadly advance Inovio's dMAb programs in infectious diseases and cancer.
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The funds will be uses in part for testing of the company's new drug candidates, which include a potential treatment of HPV-related cervical pre-cancer.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 13) Abbott Laboratories (NYSE: ABT ) Ionis Pharmaceuticals ...
The notes will be sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The notes will be senior unsecured obligations of Inovio and will accrue interest payable in cash semi-annually in arrears at a rate of 6.50% per annum. Thereafter, the notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date.